In another study, there was no association between CD3+ TILs and outcomes in ovarian cancer patients, but the survival period in groups with a high CD8+/CD4+ ratio was longer than that in groups with low CD8+/CD4+ ratio (high CD8+/CD4+ ratio survival period, 74 months; low CD8+/CD4+ ratio survival length, 25 months; hazard ratio = 0.31, p = 0.0002) [40]. This evidence concerns the gene CD8A and ovarian cancer.